Cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) compared to lamivudine as first line treatment of chronic hepatitis B (CHB) in the UK

被引：0
|
作者：
Veenstra, DL
Sullivan, SD
Dusheiko, GM
Jacobs, M
Lewis, GJ
Patel, KK
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Royal Free Hampstead NHS Trust, London, England
[3] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[4] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A120 / A120
页数：1
相关论文
共 50 条
  • [21] HBeAg-positiye chronic hepatitis B (CHB) patients with difficult-to-treat disease improved response rates with peginterferon alfa-2a (40KD) (pegasys®) compared with conventional
    Graham, W
    Cooksey, E
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chang, WY
    Zahm, FE
    Pluck, N
    HEPATOLOGY, 2002, 36 (04) : 374A - 374A
  • [22] Role of baseline and on-treatment quantitative HBeAg in predicting response to peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy in chronic hepatitis B
    Fried, Michael W.
    Lau, George K. K.
    Liaw, Yun-Fan
    Luo, Kang-Xian
    Piratvisuth, Teerha
    Cooksley, Graham
    Marcellin, Patrick
    Thongsawat, Satawat
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A72 - A72
  • [23] Effect of ethnicity on the pharmacokinetics of ribavirin (COPEGUS®) and peginterferon alfa-2a (40kd) (PEGASYS®) in patients with chronic hepatitis C
    Brennan, B
    Morrison, R
    Hagedorn, C
    Marbury, TC
    Sulkowski, M
    Grippo, J
    Gries, JM
    HEPATOLOGY, 2005, 42 (04) : 652A - 653A
  • [24] Evidence for the efficacy of peginterferon alfa-2a (40 KD) (pegasys) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors
    Cooksley, WGE
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    JOURNAL OF HEPATOLOGY, 2002, 36 : 8 - 8
  • [25] Combination of Levovirin (LVV) and peginterferon alfa-2a (40 KD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40KD) in patients with chronic hepatitis
    Pockros, PJ
    Pessoa, MG
    Diago, M
    Martinelli, ADC
    Berg, T
    Germanidis, G
    Lai, MY
    Gomez, HR
    Goeser, T
    Roberts, S
    Sheen, IS
    Hsien, T
    Hinrichsen, HM
    Lee, SS
    Reindollar, R
    Sola, R
    Wilson, K
    Jorga, K
    Graham, P
    Jackson, H
    HEPATOLOGY, 2004, 40 (04) : 391A - 391A
  • [26] Cost-effectiveness of early treatment of chronic hepatitis c with peginterferon Alfa-2a (40KD) plus ribavirin before progression to advanced liver disease
    Hornberger, John
    Pockros, Paul
    Chu, Teng-Chiao
    Patel, Kavita K.
    Shiffman, Mitchell I.
    GASTROENTEROLOGY, 2007, 132 (04) : A788 - A788
  • [27] Characterization of Hepatitis B Surface Proteins in HBeAg-positive Patients with Chronic Hepatitis B (CHB) Treated With PegInterferon Alfa-2a (40KD)
    Rinker, Franziska
    Bremer, Corinna M.
    Wiegand, Steffen B.
    Bremer, Birgit
    Manns, Michael P.
    Wedemeyer, Heiner
    Yang, Lei
    Pavlovic, Vedran
    Wat, Cynthia
    Glebe, Dieter
    Kraft, Anke R.
    Cornberg, Markus
    HEPATOLOGY, 2015, 62 : 1196A - 1197A
  • [28] HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Drakoulis, C.
    Bakalos, G.
    Papatheodoridis, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S286 - S287
  • [29] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [30] Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS®) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone
    Germanidis, G
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Yao, GB
    Piratvisuth, T
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Popescu, M
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 653A - 653A
12345